ClinicalTrials.gg

Program

XTMAB-16

A development code. Also written as “XTMAB-16 2 mg/kg” and “XTMAB-16 4mg/kg”.

Its studies are mostly in Sarcoidosis, Pulmonary, led by Xentria.

Furthest: phase 2, since Nov 17, 20233 company-led studies, 1 open or runningNext primary completion: Oct 31, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Xentria31 open or runningphase 2since Nov 17, 2023Jul 7, 2021Oct 31, 2029phase 2 · NCT07680166

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 7, 2021First study: phase 1 study in Healthy ParticipantsFirst studyNCT04971395 · 25 enrolled · United States
  2. Nov 17, 2023Phase 2 study in Sarcoidosis, PulmonaryNCT06169397 · 31 enrolled · United States, Czechia, Poland and more
  3. Jun 25, 2026Phase 2 study in Sarcoidosis, PulmonaryNCT07680166 · 182 planned

Ahead

  1. Oct 31, 2029Primary completion: phase 2 study in Sarcoidosis, PulmonaryNCT07680166

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07680166Sarcoidosis, Pulmonary2Not yet recruitingOct 31, 2029182
NCT06169397Sarcoidosis, Pulmonary · United States, Czechia, Poland and more2CompletedOct 9, 202631
NCT04971395Healthy Participants · United States1CompletedMar 18, 202225

How it is read

Names in the registry

  • “XTMAB-16”, 2 entries
  • “XTMAB-16 2 mg/kg”, 1 entry
  • “XTMAB-16 4mg/kg”, 1 entry

Codes read as this program: XTMAB16.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.